A retrospective study to assess treatment patterns, all-cause and Myelofibrosis-related health care resource utilization, and costs in adults with myelofibrosis
Latest Information Update: 06 May 2022
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
Most Recent Events
- 06 May 2022 New trial record
- 11 Mar 2022 Results published in the Oncologist